Valneva SE operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Valneva SE with three other
pharmaceutical manufacturers in Europe:
Moberg Pharma AB (publ)
sales of 285.57 million Swedish Kronor [US$32.45 million]
of which 55%
was Nalox/Kerasal Nail, Sales of prodcuts),
(26.37 million Euro [US$28.48 million]
Horizon Discovery Group PLC
based in the United Kingdom
(£20.16 million [US$25.16 million]
of which 60%
During the year ended December of 2015, sales at
Valneva SE were 78.36 million Euro (US$84.62 million).
increase of 112.2%
versus 2014, when the company's sales were 36.92 million Euro.
This was the third consecutive year of growth at Valneva SE.
Sales of Technologies and Services saw an increase
148.5% in 2015, from
5.07 million Euro to 12.59 million Euro.
Not all segments of Valneva SE experienced an increase in sales in 2015:
sales of Vaccine Candidates fell 4.2% to 8.69 million Euro.